Esketamine (Spravato™), an intranasal medication related to ketamine, was recently approved by the FDA for treatment-resistant depression. It is chemically related to ketamine, which is also used for depression. Given intranasally, esketamine must be administered and monitored in an approved clinic, and will require 2 hours of observation in the clinic following each administration.
An evaluation in the office is required before approval for ketamine treatment, even if you have received ketamine treatments somewhere else in the past. The course of treatment is twice a week for 4 weeks, then weekly to every other week indefinitely.
